Europe The new president of Medicines for Europe, Elisabeth Stampa, outlines one of the priorities of her mandate: working to adjust the EU pharma policy framework to improve access for patients across Europe. Regulatory flexibilities implemented during COVID-19 showed that the EU system can require one of highest safety, quality…
Australia Writing in April edition of DIA’s Global Forum magazine, the University of New South Wales’s Richard Day looks at Australia’s National Medicines Policy (NMP) and how it is being reshaped by community and stakeholder feedback. Australia’s National Medicines Policy (NMP), gazetted in 2000, is being revised and the draft policy was…
USA The latest from US health care policy, including the Senate budget deal funding for a range of major health care priorities; Biden’s proposed Advanced Research Projects Agency that would reshape the government’s medical research efforts; the Senate Finance Chair’s proposal to lower prescription drug prices; the FDA’s internal investigation into…
Opinion In his latest piece, Brendan Shaw casts his eye over why those drawing up health policies need to start incorporating issues of industrial policy into their long-term planning in order to secure investments into the right kinds of R&D and to help build a more open and collaborative innovation ecosystem.…
Czech Republic Martin Balada and Kateřina Podrazilová from the Association of Health Insurance Companies of the Czech Republic (SZP ČR) give a thorough insight into the current dialogues surrounding pricing and reimbursement, set to deeply impact access to highly innovative and orphan drugs in the country. Furthermore, they evaluate the uniqueness of…
Opinion Eurasia Group’s Aditya Bhattacharji tackles three more key geopolitical issues that global pharma needs to be cognizant of: the world’s leading drug regulators becoming increasingly strident and active beyond national borders; the impact that greater awareness and work on climate change could have on the industry; and the risks surrounding…
Taiwan In an effort to enhance trade and cooperation with other countries in the region and reduce dependency on mainland China, in 2016 Taiwan’s government introduced the New Southbound Policy (NSP). The policy has been designed to leverage educational, technological, and economic assets to enhance Taiwan’s regional integration and increased medical…
Canada It is not a secret anymore, many in the industry now know that Health Canada is working on a new version of the policy entitled: The Distinction Between Advertising and Other Activities, dated more than 20 years ago. Earlier this week, Health Canada provided some insights about the reformed policy…
Opinion The Foundations for Evidence-Based Policy-Making Act, recently signed into law in the USA, stands to make government data more accessible; thereby allowing researchers, statisticians and others inside and outside of government to make better, and evidenced-based, policy decisions. Carla Smith outlines the scope of the Act and its potential implications…
China In late 2018 China adopted a novel procurement scheme with the aim of dramatically cutting the amount being paid for generic drugs. The policy’s effect on pricing stands to hit domestic generic firms hardest unless they adapt their business models. Big Pharma could also lose out as their off-patent originators…
Malaysia Dr. Azrul Mohd Khalib, chief executive at the Galen Centre for Health and Social Policy, gives an insight on the current important issues the Malaysian healthcare ecosystem is facing and the different solutions and strategies the Galen Centre, as a thinktank for health and social issues, has identified for the…
Turkey In 2016 the Turkish Medicine and Medical Devices Agency (TiTCK) implemented a localisation policy to reduce Turkey’s reliance on imports – a few years later, it has created a young, ambitious export sector. Turkey’s experiment with mandatory localisation policies for pharmaceutical and medical products production is paying off nicely.…
See our Cookie Privacy Policy Here